search
Back to results

Modulating Exercise Dosage to Improve Concussion Recovery (MEDIC)

Primary Purpose

Concussion, Brain, Treatment, Aerobic Exercise

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
High Dose Exercise
Sponsored by
University of Colorado, Denver
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Concussion, Brain focused on measuring intervention, mild traumatic brain injury

Eligibility Criteria

13 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 13-18 years of age
  • Post-Concussion Symptom Scale (PCSS) score >10 to ensure participants are not recovered by enrollment
  • Concussion diagnosis by a sports medicine physician

Exclusion Criteria:

  • Pre-existing neurological disorders
  • Exercise contraindications
  • Concussion <6 months before enrollment (excluding the current injury)

Sites / Locations

  • University of Colorado DenverRecruiting
  • Boston Children's HospitalRecruiting
  • Spaulding Rehabilitation HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

High Dose Exercise

Standard-of-care

Arm Description

The investigators will provide exercise dose recommendations for initial visit until symptom resolution, and revise upon symptom resolution (to use for the subsequent 8 weeks). These include intensity (target HR) and volume (frequency/duration). Intensity is calculated as 90% of the HR at the end of the exercise test. The volume recommendation is 150 mins/week (~30 min/day; 5 days/week). The mode of exercise is another consideration. This will be left to participant preference, so that the investigators do not exclude potential participants due to lack of access to specific exercise equipment.

Participants are instructed to perform activity in line with physician recommendations. This consists of a general recommendation (no specific HR/volume) or symptom limited physical activity.

Outcomes

Primary Outcome Measures

Time from injury to symptom resolution
The PCSS is a standard form that records the presence and severity of 22 concussion symptoms at the time of testing. Participants rate their concussion symptoms from 0-6 where 0 equates to "no symptoms," and 6 to "severe symptoms."
Serum biomarker concentration: GFAP change
Concentrations of GFAP will be simultaneously assayed along with other biomarkers using multi-plex digital array technology, which allows for single molecule immunoarrays while minimizing the amount of sample required
Anxiety and depression severity change
Participants will report anxiety using the Hospital Anxiety and Depression Scale (HADS).The HADS addresses questions related to depression and anxiety symptoms. Responses range from 0 to 3, where 3=experiencing symptoms a great deal of the time, on 14 questions. Seven items are specific to depression symptoms, and 7 to anxiety symptoms. For each sub-scale (HADS-anxiety and HADS-depression) scores range from 0 (no symptoms) to 21 (maximum symptom severity).

Secondary Outcome Measures

Serum biomarker concentration: IL-6 change
Concentrations of IL-6 will be simultaneously assayed along with other biomarkers using multi-plex digital array technology, which allows for single molecule immunoarrays while minimizing the amount of sample required
Serum biomarker concentration: TNF-alpha change
Concentrations of TNF-alpha will be simultaneously assayed along with other biomarkers using multi-plex digital array technology, which allows for single molecule immunoarrays while minimizing the amount of sample required
Serum biomarker concentration: IL1-RA change
Concentrations of IL1-RA will be simultaneously assayed along with other biomarkers using multi-plex digital array technology, which allows for single molecule immunoarrays while minimizing the amount of sample required
Serum biomarker concentration: VEGF change
Serum biomarkers will be obtained via venipuncture at the initial visit, after symptom resolution, and 8 weeks after symptom resolution.
Serum biomarker concentration: MMP-9 change
Concentrations of MMP-9 will be simultaneously assayed along with other biomarkers using multi-plex digital array technology, which allows for single molecule immunoarrays while minimizing the amount of sample required
Cerebral autoregulation
The investigators will examine the ability to buffer against pressure changes during exercise. Autoregulation will be assessed by deriving the relationship between arterial pressure and cerebral blood flow fluctuations elicited using low resistance breathing.
Cerebral vasoreactivity change
The investigators will examine the ability to increase blood flow in response to increases in blood CO2. This is assessed by measuring the progressive increase in cerebral blood flow in response to progressive increases in inspired CO2.
Kinesiophobia severity change
The Tampa Scale of Kinesiophobia (TSK) is a 17-item self-report, 4-point Likert scale questionnaire designed to assess fear of pain with movement (kinesiophobia). The questionnaire was originally designed to measure fear of pain during movement among patients with low back pain, and is reliable.
Peer relationship attitudes change
Using the Patient Reported Outcomes Measurement Information System (PROMIS), The investigators will obtain data regarding participant attitudes toward peer relationships (friends and other acquaintances).
Academic concerns change
The Concussion Learning Assessment and School Survey (CLASS) aims to assess concern for the effect of concussion on school learning, new or exacerbated post-concussion academic problems, and perceived impact on academic performance.

Full Information

First Posted
May 26, 2022
Last Updated
October 18, 2023
Sponsor
University of Colorado, Denver
Collaborators
Boston Children's Hospital, Spaulding Rehabilitation Hospital, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
search

1. Study Identification

Unique Protocol Identification Number
NCT05434130
Brief Title
Modulating Exercise Dosage to Improve Concussion Recovery
Acronym
MEDIC
Official Title
Modulating Exercise Dosage to Improve Concussion Recovery: A Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 5, 2022 (Actual)
Primary Completion Date
October 31, 2026 (Anticipated)
Study Completion Date
October 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver
Collaborators
Boston Children's Hospital, Spaulding Rehabilitation Hospital, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Aerobic exercise has emerged as an effective treatment to reduce sport-related concussion symptom severity, yet existing work lacks rigor regarding the precise exercise volume and intensity required to elicit therapeutic effects, how exercise can alter concussion-related pathophysiology, and whether exercise can prevent the development of secondary sequelae. Our objective is to examine if a high dose exercise program (higher volume than currently prescribed at an individualized, safe intensity level) initiated within 14 days of concussion results in faster symptom resolution, altered physiological function, or reduced secondary sequalae. Findings from this research will lead to more rigorous and precise rehabilitation guidelines and improved understanding about how exercise affects neurophysiological function among adolescents with concussion.
Detailed Description
Concussions are defined as a mild form of traumatic brain injury that result in acute neurological dysfunction. Recent work suggests post-concussion aerobic exercise at an intensity level below symptom exacerbation is safe. Yet, clinical benefits from existing randomized controlled trials indicate substantial room for improvement. Also, there is currently an incomplete understanding of the neurophysiology underlying changes in response to exercise treatment. Identifying the precise exercise dose (volume/intensity) required to elicit a therapeutic response following concussion will lead to enhanced and more precise post-concussion rehabilitation strategies. Published and pilot data by the investigators indicate light post-concussion exercise was associated with faster symptom resolution time and less severe symptoms, yet this relied on self-reported data and observational designs. Furthermore, the investigators have identified that the optimal exercise volume to differentiate those with/without concussion symptoms after one month was >160 minutes/week, which is higher than standard exercise volumes prescribed (>100 minutes/week), and in line with existing recommendations for cardiovascular health (>150 minutes/week). Beyond this, given the positive effects of regular moderate exercise to reduce inflammation (e.g., interleukin 6) and restore cerebrovascular regulation, these physiological functions represent viable and feasible rehabilitation targets. Thus, using a prospective randomized clinical trial design, the investigators aim to identify if high dose exercise >(150 minutes/week at an individualized intensity level), relative to standard-of-care, results in: faster/slower symptom resolution, altered physiological function, or reduced secondary sequalae. Our multidisciplinary investigative team has expertise investigating concussion, exercise physiology, fluid biomarkers, cerebrovascular physiology, and psychosocial outcomes. Thus, the investigators will enroll, initially test, and randomize adolescents ages 13-18 years old ≤14 days post-concussion to high dose aerobic exercise or standard-of-care (symptom limited, self-guided physical activity), and reassess upon symptom resolution and 8-weeks post symptom resolution. The investigators will obtain cerebrovascular function and serum biomarker data at each visit, and quantify exercise, symptoms, and secondary sequalae continuously. First, The investigators aim to examine how the dose (intensity, duration, and frequency) of an aerobic exercise program initiated within 10 days of concussion affects time to symptom resolution, relative to standard-of-care, among adolescents. Second, the investigators aim to assess the mechanistic relationship between aerobic exercise, biomarkers of neuroinflammation, and cerebrovascular function. Third, the investigators aim to elucidate how high dose exercise after concussion affects persistent secondary sequalae development (anxiety, depression, kinesiophobia, peer relationships, academic concerns). By challenging the currently accepted, exercise recommendations for sport-related concussion, the investigators will break new ground toward improving rehabilitation strategies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Concussion, Brain, Treatment, Aerobic Exercise, Inflammation, Depression, Anxiety
Keywords
intervention, mild traumatic brain injury

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
The study will use a block stratified RCT design. Our stratum factors are the biological variable of sex and recruitment location
Masking
InvestigatorOutcomes Assessor
Masking Description
The study PI, Co-Is, and the biostatistician will not know group assignments until after the primary analyses are complete.
Allocation
Randomized
Enrollment
216 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
High Dose Exercise
Arm Type
Experimental
Arm Description
The investigators will provide exercise dose recommendations for initial visit until symptom resolution, and revise upon symptom resolution (to use for the subsequent 8 weeks). These include intensity (target HR) and volume (frequency/duration). Intensity is calculated as 90% of the HR at the end of the exercise test. The volume recommendation is 150 mins/week (~30 min/day; 5 days/week). The mode of exercise is another consideration. This will be left to participant preference, so that the investigators do not exclude potential participants due to lack of access to specific exercise equipment.
Arm Title
Standard-of-care
Arm Type
No Intervention
Arm Description
Participants are instructed to perform activity in line with physician recommendations. This consists of a general recommendation (no specific HR/volume) or symptom limited physical activity.
Intervention Type
Behavioral
Intervention Name(s)
High Dose Exercise
Intervention Description
The investigators will initially test and randomize adolescents ages 13-18 years old ≤14 days post-concussion to high dose aerobic exercise (>150 min/week, individualized intensity level) or standard-of-care (symptom limited, self-guided physical activity), and re-test upon symptom resolution and 8-weeks post symptom resolution
Primary Outcome Measure Information:
Title
Time from injury to symptom resolution
Description
The PCSS is a standard form that records the presence and severity of 22 concussion symptoms at the time of testing. Participants rate their concussion symptoms from 0-6 where 0 equates to "no symptoms," and 6 to "severe symptoms."
Time Frame
From time of injury until defined symptom resolution observed, about 30 days
Title
Serum biomarker concentration: GFAP change
Description
Concentrations of GFAP will be simultaneously assayed along with other biomarkers using multi-plex digital array technology, which allows for single molecule immunoarrays while minimizing the amount of sample required
Time Frame
Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)
Title
Anxiety and depression severity change
Description
Participants will report anxiety using the Hospital Anxiety and Depression Scale (HADS).The HADS addresses questions related to depression and anxiety symptoms. Responses range from 0 to 3, where 3=experiencing symptoms a great deal of the time, on 14 questions. Seven items are specific to depression symptoms, and 7 to anxiety symptoms. For each sub-scale (HADS-anxiety and HADS-depression) scores range from 0 (no symptoms) to 21 (maximum symptom severity).
Time Frame
Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)
Secondary Outcome Measure Information:
Title
Serum biomarker concentration: IL-6 change
Description
Concentrations of IL-6 will be simultaneously assayed along with other biomarkers using multi-plex digital array technology, which allows for single molecule immunoarrays while minimizing the amount of sample required
Time Frame
Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)
Title
Serum biomarker concentration: TNF-alpha change
Description
Concentrations of TNF-alpha will be simultaneously assayed along with other biomarkers using multi-plex digital array technology, which allows for single molecule immunoarrays while minimizing the amount of sample required
Time Frame
Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)
Title
Serum biomarker concentration: IL1-RA change
Description
Concentrations of IL1-RA will be simultaneously assayed along with other biomarkers using multi-plex digital array technology, which allows for single molecule immunoarrays while minimizing the amount of sample required
Time Frame
Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)
Title
Serum biomarker concentration: VEGF change
Description
Serum biomarkers will be obtained via venipuncture at the initial visit, after symptom resolution, and 8 weeks after symptom resolution.
Time Frame
Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)
Title
Serum biomarker concentration: MMP-9 change
Description
Concentrations of MMP-9 will be simultaneously assayed along with other biomarkers using multi-plex digital array technology, which allows for single molecule immunoarrays while minimizing the amount of sample required
Time Frame
Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)
Title
Cerebral autoregulation
Description
The investigators will examine the ability to buffer against pressure changes during exercise. Autoregulation will be assessed by deriving the relationship between arterial pressure and cerebral blood flow fluctuations elicited using low resistance breathing.
Time Frame
Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)
Title
Cerebral vasoreactivity change
Description
The investigators will examine the ability to increase blood flow in response to increases in blood CO2. This is assessed by measuring the progressive increase in cerebral blood flow in response to progressive increases in inspired CO2.
Time Frame
Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)
Title
Kinesiophobia severity change
Description
The Tampa Scale of Kinesiophobia (TSK) is a 17-item self-report, 4-point Likert scale questionnaire designed to assess fear of pain with movement (kinesiophobia). The questionnaire was originally designed to measure fear of pain during movement among patients with low back pain, and is reliable.
Time Frame
Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)
Title
Peer relationship attitudes change
Description
Using the Patient Reported Outcomes Measurement Information System (PROMIS), The investigators will obtain data regarding participant attitudes toward peer relationships (friends and other acquaintances).
Time Frame
Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)
Title
Academic concerns change
Description
The Concussion Learning Assessment and School Survey (CLASS) aims to assess concern for the effect of concussion on school learning, new or exacerbated post-concussion academic problems, and perceived impact on academic performance.
Time Frame
Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
13 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 13-18 years of age Post-Concussion Symptom Scale (PCSS) score >10 to ensure participants are not recovered by enrollment Concussion diagnosis by a sports medicine physician Exclusion Criteria: Pre-existing neurological disorders Exercise contraindications Concussion <6 months before enrollment (excluding the current injury)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
David R Howell, PhD
Phone
7207771502
Email
ConcussionResearch@cuanschutz.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Lindsey Kemp, BS
Phone
7207771502
Email
ConcussionResearch@cuanschutz.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David R Howell, PhD
Organizational Affiliation
University of Colorado Denver | Anschutz
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Colorado Denver
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David R Howell, PhD
Phone
720-777-1502
Email
ConcussionResearch@cuanschutz.edu
First Name & Middle Initial & Last Name & Degree
Mathew Wingerson, MS
Phone
7207771502
Email
ConcussionResearch@cuanschutz.edu
Facility Name
Boston Children's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Danielle Hunt, MS
First Name & Middle Initial & Last Name & Degree
William P Meehan III, MD
Facility Name
Spaulding Rehabilitation Hospital
City
Cambridge
State/Province
Massachusetts
ZIP/Postal Code
02138
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrew Taylor, PhD
First Name & Middle Initial & Last Name & Degree
J Andrew Taylor, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Modulating Exercise Dosage to Improve Concussion Recovery

We'll reach out to this number within 24 hrs